Eli Lilly expects Alzheimer’s drugs to gain wider approval from Medicare

Eli Lilly & Co. expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients, Reuters reports. Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June. More study data on Leqembi, a rival drug from partners Eisai Co. Ltd. and Biogen Inc., is also expected in the coming months.